Q4 2022 13F Holders as of 12/31/2022
-
Type / Class
-
Equity / Common Stock, par value $0.01 per share
-
Shares outstanding
-
34.7M
-
Number of holders
-
76
-
Total 13F shares, excl. options
-
18M
-
Shares change
-
+297K
-
Total reported value, excl. options
-
$306M
-
Value change
-
+$821K
-
Put/Call ratio
-
0.15
-
Number of buys
-
40
-
Number of sells
-
-36
-
Price
-
$17.01
Significant Holders of IGM Biosciences, Inc. - Common Stock, par value $0.01 per share (IGMS) as of Q4 2022
94 filings reported holding IGMS - IGM Biosciences, Inc. - Common Stock, par value $0.01 per share as of Q4 2022.
IGM Biosciences, Inc. - Common Stock, par value $0.01 per share (IGMS) has 76 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 18M shares
of 34.7M outstanding shares and own 51.75% of the company stock.
Largest 10 shareholders include Redmile Group, LLC (3.33M shares), BAKER BROS. ADVISORS LP (3.16M shares), Artal Group S.A. (2.45M shares), PRICE T ROWE ASSOCIATES INC /MD/ (2.21M shares), ALKEON CAPITAL MANAGEMENT LLC (833K shares), BlackRock Inc. (789K shares), FMR LLC (691K shares), VANGUARD GROUP INC (577K shares), UBS ASSET MANAGEMENT AMERICAS INC (485K shares), and D. E. Shaw & Co., Inc. (390K shares).
This table shows the top 76 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.